Given the previously reported antitumor efficacy of CD40 agonists when combined with ICIs and their capacity to stimulate tumoricidal macrophage infiltration in tumors [170], if safe, these combinations are promising in bringing new hope for PCa treatment. The gene discussed is CD40; the disease is posterior cortical atrophy.